Lymphoma Program

Premier Research Program

Program Leaders: Edward Stadtmauer, MD

Since Penn's discovery of the Philadelphia Chromosome, which revolutionized cancer treatment, we've had a history of groundbreaking research.

Every day our scientists learn more about the causes of lymphoma as well as, better ways to detect and treat lymphoma. Penn continues to be on the cutting edge of designing novel treatments for hematologic malignancies, including lymphoma.

All of which can make a difference to patients and their families, both today and in the future.

Making History

  • The Lymphoma Program started in 1974, under the direction of the former Abramson Cancer Center Director, John Glick, MD, is noteworthy for the national influence of the treatment of both Hodgkin's Disease and Non-Hodgkin's Lymphoma throughout the last two decades through his leadership and direction of numerous clinical trials.
  • The Lymphoma Program pioneered the use of innovative diagnostic procedures such as the positron emission tomography (PET) in the diagnosis and treatment planning in lymphoma.
  • The Program was a pioneer in the use of chemotherapy (4HC) purged bone marrow transplantation both for non-Hodkin lymphoma (NHL) and acute myeloid leukemia (AML).

Shaping the Future of Cancer Care

  • The Lymphoma Program, under the direction of Stephen J. Schuster, MD, is one of the largest programs in the Delaware Valley.
  • A major focus of the Lymphoma research program is the development of immunologic approaches to the therapy for lymphoma. Pivotal clinical trials investigating combinations of monoclonal antibodies such as Rituximab and Epratuzumab, Rituximab and Galiximab, and radioimmunotherapy using Epratuzumab, Bexxar and Zevalin have been completed within the Program.
  • Dr. Schuster currently leads the largest NCI initiated multi-institutional trial investigating patient specific vaccination as therapy for follicular lymphoma and recently developed a promising personalized vaccine therapy to prevent recurrence among certain follicular lymphoma patients. He has also developed strategies to decrease the immune suppressive toxicities of conventional therapies for lymphoma utilizing infusion of activated autologous T-cells.
  • Other areas of active investigation include pharmacogenomic analyses of the response to monoclonal antibody therapy and mechanisms of enhancement of cytotoxicity of monoclonal antibodies.

As one of the nation's largest cancer research centers our investigators benefit each day from collaborations and interactions with over 400 scientists and physicians involved in the Abramson Cancer Center.